Lilly says retatrutide met endpoints in two more Phase 3 obesity trials
The triple agonist improved both body weight and A1C in the additional registrational studies, according to the company.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 23 03:00 ETSource: Eli Lilly
The wire
- 01Eli Lilly announced that retatrutide, its GLP-1/GIP/glucagon triple agonist, succeeded in two additional Phase 3 obesity trials, with improvements in weight and A1C.
- 02Retatrutide is the most advanced triple agonist in obesity and would sit alongside semaglutide and tirzepatide in the incretin prescribing landscape.
- 03The results come from a company announcement; full data, safety detail and peer-reviewed publication, plus any regulatory filing timeline, have yet to follow.
From the source
Read at investor.lilly.comLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C